A phase ib/ii study of mek1/2 inhibitor pd-0325901 or mek-162 with cmet inhibitor pf-02341066 in rasmt and raswt (with aberrant c-met) colorectal cancer patients

  • Description
  • Details
  • Subprojects
  • History
  • Relations
  • Publications
Project Title: A phase ib/ii study of mek1/2 inhibitor pd-0325901 or mek-162 with cmet inhibitor pf-02341066 in rasmt and raswt (with aberrant c-met) colorectal cancer patients
Project Number: CORDIS-110280
Project web address: Follow on CORDIS
Organization: Queen'S University Belfast, Ireland, Belfast
Collaborators: Royal College Of Surgeons In Ireland, IE
Università Degli Studi Di Torino, IT
The Chancellor, Masters And Scholars Of The University Of Oxford, GB
Assistance Publique - Hopitaux De Paris, FR
Belfast Health And Social Care Trust, GB
Velindre National Health Service Trust, GB
Universite Paris Descartes, FR
Fundacio Privada Institut D'Investigacio Oncologica De Vall-Hebron, ES
Pintail Ltd, IE
Universitair Ziekenhuis Antwerpen, BE
Multiplicom Nv, BE
Principal Investigators (PI): Alberto Bardelli, IT
Colleen Spence, GB
Stephen Conway, GB
Ciaran Clissmann, IE
Alix Pillot, FR
Rosaly Datchi, FR
Katarína Hanušová, CZ
Jurgen Del-Favero, BE
Marc Peeters, BE
Andrés De Kelety Alcaide, ES
Richard Adams, GB
Kate O'Brien, GB
Bryan Hennessy, IE
 
Project Description:
Colorectal cancer (CRC) is the 3rd most common cancer in Europe, and with approximately 200,000 deaths per year, it remains the 2nd most common cause of cancer death. More than half of all CRC patients develop distant metastases and have 5-year overall survival (OS) of less than 5% because of ineffective treatments. Increased understanding of cancer biology, coupled with the implementation of “omics”-based approaches, has revealed that cancer must be considered a heterogeneous disease. Historically, “one-size-fits-all” approaches have been standard practice in CRC treatment, but with the increased understanding of the molecular/genetic heterogeneity of CRC, it is clear that novel treatments must be developed and tested in selected subgroups to maximize the benefit of these new developments. MErCuRIC is a multicentre phase Ib/II clinical trial which will assess a novel therapeutic strategy (combined treatment of a MEK inhibitor PD-0325901 or MEK-162 with a MET inhibitor PF-02341066) to combat metastasis, improve survival and change current clinical practice for CRC patients with RAS mutant (MT) and RAS wild type (WT) (with aberrant c-MET) tumours. The consortium will go beyond the current state-of-the-art by (i) employing a novel treatment strategy targeting the biology of the disease and by (ii) using next generation sequencing (NGS) and ‘xenopatients’ to identify CRC patient subgroups who will maximally benefit from this novel treatment strategy.
 
Project Terms:
life sciences
Project Title: A phase ib/ii study of mek1/2 inhibitor pd-0325901 or mek-162 with cmet inhibitor pf-02341066 in rasmt and raswt (with aberrant c-met) colorectal cancer patients
Project Number: CORDIS-110280
Project web address: Follow on CORDIS
Organization: Queen'S University Belfast, Ireland, Belfast
Collaborators: Royal College Of Surgeons In Ireland, IE
Università Degli Studi Di Torino, IT
The Chancellor, Masters And Scholars Of The University Of Oxford, GB
Assistance Publique - Hopitaux De Paris, FR
Belfast Health And Social Care Trust, GB
Velindre National Health Service Trust, GB
Universite Paris Descartes, FR
Fundacio Privada Institut D'Investigacio Oncologica De Vall-Hebron, ES
Pintail Ltd, IE
Universitair Ziekenhuis Antwerpen, BE
Multiplicom Nv, BE
Principal Investigators (PI): Alberto Bardelli, IT
Colleen Spence, GB
Stephen Conway, GB
Ciaran Clissmann, IE
Alix Pillot, FR
Rosaly Datchi, FR
Katarína Hanušová, CZ
Jurgen Del-Favero, BE
Marc Peeters, BE
Andrés De Kelety Alcaide, ES
Richard Adams, GB
Kate O'Brien, GB
Bryan Hennessy, IE
 
Project Categories:
Natural Sciences > Aging Diseases and Pathology > Cancer & related diseases > Malignant neoplasms (including in situ) > Gastrointestinal cancers > Colorectal cancer
 
Other Information:
Fiscal Year: 2013
Project Start Date: 1 December 2013
Project End Date: 30 November 2020
Project program: FP7-HEALTH
 
Project Funding Information:
Funding Mechanism: CP-FP - Small or medium-scale focused research project
Year Funding Organization Total Funding, $
2013 European Research Council $8,906,468